Relative Dose Intensity of Trabectedin and Outcome of Advanced L‐Sarcomas

Relative Dose Intensity of Trabectedin and Outcome of Advanced L‐Sarcomas

ABSTRACT Background Trabectedin, which is approved for advanced soft tissue sarcoma management, has a complex mechanism of action, but can be classified as an alkylating agent. The need to maintain a high relative dose intensity (RDI) is not clearly established in this clinical setting. Methods We c...

Full description

Saved in:
Bibliographic Details
Main Authors: Stephen Poitureau, Marie‐Cécile Le Deley, Mehdi Brahmi, Emmanuelle Bompas, Jean‐Emmanuel Kurtz, Simon Nannini, Christophe Perrin, Loïc Lebellec, Thomas Ryckewaert, Redha Ould‐Ammar, Clémence Leguillette, Jean‐Yves Blay, Nicolas Penel
Format: Article
Language:English
Published: Wiley 2025-08-01
Series:Cancer Medicine
Subjects:
dose reduction
relative dose intensity
soft tissue sarcoma
toxicity
trabectedin
Online Access:https://doi.org/10.1002/cam4.71131
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/cam4.71131

Similar Items